Charles Schwab Investment Management Inc. Buys 84,904 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Charles Schwab Investment Management Inc. increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 7.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,269,513 shares of the biopharmaceutical company's stock after purchasing an additional 84,904 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.82% of TG Therapeutics worth $38,212,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Blue Trust Inc. raised its stake in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares during the period. Smartleaf Asset Management LLC raised its stake in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 1,594 shares during the period. Jones Financial Companies Lllp lifted its holdings in TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC bought a new position in TG Therapeutics during the fourth quarter worth about $75,000. Finally, GAMMA Investing LLC increased its stake in shares of TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 2,171 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 10.50% of the company's stock.

TG Therapeutics Price Performance

Shares of TGTX stock traded up $2.36 on Wednesday, reaching $42.24. The company's stock had a trading volume of 1,501,734 shares, compared to its average volume of 2,972,584. The company has a market capitalization of $6.63 billion, a P/E ratio of -422.41 and a beta of 2.30. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $42.34. The stock's 50 day simple moving average is $32.35 and its 200-day simple moving average is $29.32. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TGTX has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research note on Monday, November 25th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.